ADIHEX
18.5.2020 22:50:10 CEST | Business Wire | Press release
The Higher Organizing Committee of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) has announced that the 18th edition of the exhibition, which was scheduled for 29th September - 3rd October 2020, will be rescheduled to September 2021, under the theme of ‘Sustainability and Heritage… A Reborn Aspiration’.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005737/en/
The 18th edition of ADIHEX will be organised by the Emirates Falconers’ Club at the Abu Dhabi National Exhibition Centre (ADNEC), under the patronage of HH Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in Al Dhafra Region and Chairman of Emirates Falconers’ Club.
The decision to postpone the exhibition for a year was taken in consideration due to the COVID-19 pandemic outbreak, to ensure the health and safety of all participants and visitors.
H.E. Majid Ali Al Mansouri, Chairman of the Higher Organizing Committee of the exhibition has revealed major changes for exhibitors and visitors including enhancing the quality of its exhibits, products, and unique innovations from the world of hunting and equestrian; maintaining ADIHEX’s profile as the largest annual event of its kind in the Middle East and Africa.
The comprehensive expansion plan also includes improving the content of the event by providing innovative services, technologies, activities, and events with a renewed vision, strengthening the exhibition’s role in preserving the UAE’s heritage and promoting sustainable hunting. This is in addition to organizing more environmental, heritage, art, educational and awareness-raising activities.
ADIHEX continues in its effort to achieve its mission by developing long-term plans in line with the national strategy of celebrating UAE’s five decades of achievements in 2021 and preparing for the coming 50 years with an ambitious vision which looks towards the future. This combined with a commitment to excellence and competitiveness will align the exhibition with the governments directives to enter the new phase with determination and persistence.
As the number of exhibitors has multiplied more than 16 times over the past editions, ADIHEX 2019 hosted more than 650 companies and brands from 41 countries in an exhibition area of 45,000 square meters.
ADIHEX also enjoys great popularity around the world and is awaited by many - individuals and families- year after year, as a record of more than 1,500,000 people visited the exhibition over the past 17 editions.
ADIHEX is a non-profit event initiated in Abu Dhabi by the UAE's Founding Father, the late Sheikh Zayed bin Sultan Al Nahyan who honoured the first edition in 2003 by visiting the event. Since its inauguration, ADIHEX has become a benchmark for B2B and B2C events and one of the key events organized within the UAE.
ADIHEX provides its participants and visitors with a comprehensive offering within its 11 sectors which are: veterinary products and services, hunting guns, media, outdoor leisure vehicles and equipment, hunting tourism and safari, arts and crafts, equestrian, falconry, fishing and marine sports, hunting and camping equipment and finally cultural heritage.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005737/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom